Assessing Progyny’s 71% Price Gap Following Analyst Upgrades in 2025
If you are on the fence about Progyny, you are not alone. Investors are weighing whether to stick with this fertility benefits innovator or look for opportunities elsewhere. If you have watched the stock chart lately, you know it has been anything but smooth. Over the past week, Progyny dipped 7.1%, and it is down 11.3% for the past month. That might sound troubling, but zoom out and the story is surprisingly nuanced. Progyny is still up 12.8% year-to-date and a solid 22.5% over the past year. However, longer-term holders have experienced more turbulence, with three- and five-year returns sitting at -47.8% and -31.6% respectively.
Some of this whiplash can be traced to shifting perceptions of risk in the digital health and benefits…
